Autifony Therapeutics hosts symposium ‘Schizophrenia: a treatable brain disorder’ at British Association for Psychopharmacology

21 July 2014

London – UK – 21st July 2014 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and serious disorders of the nervous system, today hosted a satellite symposium at the British Association for Psychopharmacology 40th Anniversary Summer Meeting to raise the profile of its pioneering new schizophrenia programme, now in preclinical development.